Duvakitug is an investigational human monoclonal antibody targeting TL1A for inflammatory bowel disease, specifically ulcerative colitis and Crohn's disease. Phase 2b induction and long-term extension data showed durable efficacy signals, and phase 3 programs are ongoing. The therapy has not been reviewed for approval by regulatory authorities.
Blackstone closed its sixth dedicated life sciences fund at a $6.3 billion hard cap, the largest private fund raised for the sector. The vehicle is nearly 40% larger than its 2020 predecessor and targets late-stage drug assets.
Teva and Sanofi reported durable 44-week efficacy for duvakitug in inflammatory bowel disease, while the FDA accepted Teva's application for TEV-749, a once-monthly olanzapine injection for schizophrenia.
Teva and Sanofi reported positive 44-week data from the RELIEVE UCCD long-term extension study of duvakitug, showing durable efficacy in ulcerative colitis and Crohn's disease patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07185009 |
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis |
RECRUITING | PHASE3 |
| NCT07184996 |
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis |
RECRUITING | PHASE3 |
| NCT07184944 |
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease |
RECRUITING | PHASE3 |
| NCT07184931 |
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease |
RECRUITING | PHASE3 |
